Journal ArticleOPEN ACCESS

Thalidomide for the Treatment of Chronic Graft-versus-Host Disease

  • Vogelsang G
  • Farmer E
  • Hess A
  • et al.
New England Journal of Medicine (1992) 326(16) 1055-1058
DOI: 10.1056/nejm199204163261604
411Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

Abstract

Allogeneic bone marrow transplantation is an accepted therapy for hematologic cancer, aplastic anemia, and inherited immunodeficiencies. Chronic graft-versus-host disease (GVHD) is the principal complication in patients surviving more than 100 days. Thalidomide has been shown experimentally to be effective in treating GVHD.

Cite

CITATION STYLE

APA

Vogelsang, G. B., Farmer, E. R., Hess, A. D., Altamonte, V., Beschorner, W. E., Jabs, D. A., … Santos, G. W. (1992). Thalidomide for the Treatment of Chronic Graft-versus-Host Disease. New England Journal of Medicine, 326(16), 1055–1058. https://doi.org/10.1056/nejm199204163261604

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free